Organovo (NASDAQ:ONVO) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO) in a research report sent to investors on Thursday. The brokerage issued a sell rating on the medical research company’s stock.

Organovo Trading Up 3.6 %

Shares of ONVO opened at $0.36 on Thursday. Organovo has a 12 month low of $0.32 and a 12 month high of $1.74. The firm has a fifty day simple moving average of $0.40 and a 200 day simple moving average of $0.47. The stock has a market capitalization of $5.56 million, a price-to-earnings ratio of -0.34 and a beta of 0.56.

Organovo (NASDAQ:ONVO) last posted its quarterly earnings results on Friday, November 8th. The medical research company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.12. Organovo had a negative return on equity of 249.28% and a negative net margin of 12,176.70%. The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.04 million. As a group, research analysts predict that Organovo will post -0.77 earnings per share for the current fiscal year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.